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Abstract
Cartilage-hair hypoplasia (CHH) is an autosomal recessive syndromic immunode-
ficiency with skeletal dysplasia, short stature, hypotrichosis, variable degree of im-
mune dysfunction and increased incidence of anaemia, Hirschsprung disease and 
malignancy. CHH is caused by variants in the RMRP gene, encoding the untranslated 
RNA molecule of the mitochondrial RNA-processing endoribonuclease, which par-
ticipates in for example cell cycle regulation and telomere maintenance. Recent stud-
ies have expanded our understanding of the complex pathogenesis of CHH. Immune 
dysfunction has a major impact on clinical course and prognosis. Clinical features 
of immune dysfunction are highly variable, progressive and include infections, lung 
disease, immune dysregulation and malignancy. Mortality is increased compared 
with the general population, due to infections, malignancy and pulmonary disease. 
Several risk factors for early mortality have been reported in the Finnish CHH cohort 
and can be used to guide management. Newborn screening for severe combined im-
munodeficiency can possibly be of prognostic value in CHH. Regular follow-up by a 
multidisciplinary team should be implemented to address immune dysfunction in all 
patients with CHH, also in asymptomatic cases. Haematopoietic stem cell transplan-
tation can cure immune dysfunction, but its benefits in mildly symptomatic patients 
with CHH remain debatable. Further research is needed to understand the mecha-
nisms behind the variability of clinical features, to search for potential molecular 
treatment targets, to examine and validate risk factors for early mortality outside the 
Finnish CHH cohort and to develop management guidelines. This review focuses on 
the pathogenesis, clinical course and management of CHH.
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1 |  INTRODUCTION
Cartilage-hair hypoplasia (CHH, OMIM # 250250) is a rare 
form of skeletal dysplasia, but also a syndromic primary im-
munodeficiency disorder. The first reports of patients with 
CHH date back to the 1960s and describe the main clinical 
features of metaphyseal dysplasia, short-limbed short stature, 
sparse and fine hair, Hirschsprung disease and unusual in-
fections, for example, fatal varicella.1,2 In 1990s, additional 
patient series demonstrated that the majority of subjects with 
CHH had defective immunity and increased susceptibility to 
infections.3,4 The associated growth failure leads to severe 
disproportionate short stature, adult heights ranging on av-
erage from 110 to 140 cm.4 Other clinical features, such as 
anaemia and high incidence of malignancy, particularly lym-
phoma, contributing significantly to overall mortality, have 
been reported in 2000s.5-7
This autosomal recessive condition is caused by vari-
ants in the non-coding RNA gene RMRP (RNA component 
of the mitochondrial RNA-processing endoribonuclease, 
RNase MRP).8 CHH is enriched in the Amish and Finnish 
populations, with respective incidence of 1 in 1340 and 1 in 
23 000 births.3 Although the pathogenesis of CHH remains 
incompletely understood, the defective RMRP functioning 
ultimately impairs cell proliferation and differentiation.9,10 
Here, we review current knowledge and recent advances in 
understanding the disease pathogenesis, clinical course and 
management of CHH.
2 |  THE PATHOGENESIS OF 
IMMUNODEFICIENCY IN CHH
2.1 | The impact of RMRP variants
The human RNase MRP complex, which includes the RNA 
component RMRP and ten associated proteins, is a ubiqui-
tously expressed endoribonuclease (Figure  1).11,12 Distinct 
regions of the RNA component are involved in the interac-
tions with protein subunits and various RMRP variants se-
lectively reduce the efficacy of RNA-to-protein binding.13 
The RMRP gene (OMIM 157660) is located at chromosome 
9p13.3, and the transcript contains approximately 265 nu-
cleotides. Over 130 variants in RMRP have been reported 
in patients with CHH.14 While n.71A > G (NCBI reference 
sequence: NR_003051.3, previously known as n.70A > G) 
is the founder variant in the Amish and Finnish CHH popula-
tions and the most common disease-causing variant in sev-
eral other populations, it has not been reported in Brazilian 
or Japanese cohorts of patients with CHH.15-17 Most of the 
CHH-associated variants locate to the transcribed region but 
several variants and deletions and duplications in the pro-
moter region have also been reported.12
Duplications in the promoter region, but also variants in 
the transcribed region, lead to the reduced (but not absent) ex-
pression levels of RMRP.11,18 While variants in the promoter 
region can directly reduce RNA expression levels, variants in 
the transcribed region lead to RNA instability, probably im-
pair the secondary structure of RMRP itself or RNase MRP 
complex, reducing its enzymatic activity (Figure  1).12,18,19 
Homozygous variants in the promoter region have only rarely 
been described, suggesting the incompatibility of RMRP ab-
sence with life.12
Genotype does not correlate with clinical severity in CHH, 
and highly variable phenotype has been described in siblings 
with identical RMRP variants.4,20 This variability can be ex-
plained by epigenetic factors or allelic differences. Interestingly, 
variants in POP1, encoding one of the proteins in the RNase 
MRP complex (hPOP1, Figure 1), have been described in pa-
tients with skeletal dysplasia and decreased peripheral blood 
mononuclear cell proliferation ability.21 Furthermore, variants 
in NEPRO, encoding nucleolus and neural progenitor protein 
known to interact with multiple subunits of the RNase MRP 
complex, have been recently described in a patient with skele-
tal dysplasia and hair hypoplasia.22 Further studies are needed 
to test the hypothesis of whether allelic differences in POP1 
and genes encoding other proteins of the RNase MRP com-
plex or interacting proteins can be responsible for the variabil-
ity in CHH clinical phenotype.
2.2 | Genetic and cellular effects of defective 
RNase MRP function
Transcriptome has been examined in various cell types with 
RMRP variants. In peripheral blood leucocytes, 99 up-reg-
ulated and 38 down-regulated genes have been described.11 
Of these genes, the majority play a role in the immune sys-
tem, cell cycle regulation, apoptosis or signal transduction. 
Recently, transcriptome analysis of fibroblasts from patients 
with CHH demonstrated 35 up- and 130 down-regulated 
genes. These genes are involved in chromosome organiza-
tion, DNA packaging and binding, DNA replication and cell 
cycle pathways, as well as in PI3K-Akt signalling pathway.10 
Experiments in HEK293 cells have revealed that RMRP can 
act as a reservoir for the production of small silencing RNAs 
that have been named RMRP-S1 and RMRP-S2.23 These 
RNAs up- and down-regulate over 900 genes that are related 
to bone growth and development, haematopoiesis and cancer. 
Specific RMRP variants can impair the biogenesis of these 
silencing RNAs through alterations of secondary RNA struc-
ture, possibly explaining the variable clinical phenotype and 
disease severity in CHH.
Defective cell proliferation in CHH has been demon-
strated in fibroblasts,10 granulocyte-macrophage progenitors 
from the bone marrow,24 as well as in the peripheral blood 
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T lymphocytes.25 The analysis of cell cycle in T lympho-
cytes from patients with CHH has demonstrated a higher 
proportion of cells in the G2/M phase, consistent with the 
reduced number of cell divisions and the impaired T-cell 
proliferation reported in CHH.25 T cells from patients with 
CHH also showed an increased activation-induced apoptosis. 
Fibroblasts from patients with CHH show slower growth in 
culture, as well as prolonged cell cycle due to the delay in 
progression from G2 to G1, whereas the duration of mitosis 
is normal.10
The transfection of human fibroblasts with the RMRP 
construct carrying the n.71A > G variant results in severe im-
pairment of cyclin B2 mRNA cleavage, explaining the delay 
in cell cycle progression.9,25 The degree of this cyclin mRNA 
processing defect has in turn been linked to the severity of 
immunodeficiency and haematologic abnormalities in CHH.9 
Cyclin-dependent kinase (CDK) 2 mRNA levels are lower in 
fibroblasts from patients with CHH, as are levels of regula-
tors of CDK1 target phosphorylation such as CDC25C and 
MAST-L.10 In addition, mRNA for the potent CDK inhibitor 
CDKN1A is up-regulated. These alterations are consistent 
with malfunctioning of the main CDKs promoting progres-
sion through G2 phase.
In addition to the direct effects on the cell cycle, ribosome 
biogenesis is altered in CHH. The impaired RMRP function-
ing leads to cellular accumulation of rRNA precursors, con-
sistent with a defective pre-rRNA processing.26 The degree 
of rRNA cleavage impairment has been linked to the severity 
of bone dysplasia in CHH.9
These results suggest that RMRP variants interfere with 
normal cell cycle through pleiotropic effects including al-
tered gene regulation, inadequate functioning of silencing 
RNAs and defective ribosome biogenesis. The impact of the 
RMRP variants on the functioning of other long non-coding 
RNAs and micro RNAs is yet to be discovered.
2.3 | Defective telomere maintenance
Telomeres are structures found at the ends of human chro-
mosomes. Telomeres shorten with repetitive cell divisions 
and are then elongated by telomerase to maintain genomic 
F I G U R E  1  The structure of 
human mitochondrial RNA-processing 
ribonuclease, showing ten protein subunits 
and the secondary structure of the RNA 
component RMRP. Reproduced with 
permission from Taskinen et al18
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integrity.27,28 The telomerase complex includes a non-cod-
ing RNA component TERC, a catalytic reverse transcriptase 
TERT and other proteins.29 RMRP can form a ribonucleopro-
tein complex with TERT, producing double-stranded RNAs 
that serve as precursors to siRNA and regulate RMRP expres-
sion by a negative feedback mechanism.30
Patients with CHH have shorter telomeres in the periph-
eral blood cells, measured by qPCR or by FISH.31,32 Telomere 
length is decreased in granulocytes and lymphocytes, par-
ticularly CD45RA+CD57+ mature natural killer or T lym-
phocytes, the furthest differentiated lymphocyte subset.32 
Telomere length can therefore be decreased as a consequence 
of intensified proliferative activity of limited numbers of im-
mune cells. However, telomerase activity is also impaired in 
CHH.32 In addition, many of the clinical features of CHH (short 
stature, bone marrow failure leading to anaemia and immu-
nodeficiency, increased risk of malignancy) closely resemble 
other disorders of telomere maintenance, such as dyskerato-
sis congenita.33,34 Relative telomere length measured from 
peripheral blood DNA by qPCR was significantly shorter in 
children with CHH, but not in adults, compared with healthy 
controls.31 A similar trend—less pronounced deviation from 
normal in affected adults than in affected children—has been 
observed also in patients with pathogenic variants in telomere 
machinery genes.35 These findings probably reflect the sur-
vival advantage of adult patients included in these studies.
Shortening of telomeres can trigger the activation of DNA 
damage response, which can explain the increased apopto-
sis of lymphocytes in CHH.25,35 Patients with short telomere 
syndromes can present with T-cell immunodeficiency in 
the absence of bone marrow failure, similar to patients with 
CHH.35 Moreover, T-cell abnormalities in individuals with 
telomeropathies consist of depletion of naive T cells and ac-
cumulation of effector memory CD8+ cells, echoing the typ-
ical pattern of T-cell pathology in CHH.36
Taken together, these findings suggest the pathogenetic 
role of impaired telomere maintenance in the development of 
immunologic abnormalities in CHH.
2.4 | Animal models of CHH
Attempts to generate a mouse model of CHH have failed due 
to the essential function of RMRP in early mouse develop-
ment.37 The insertion of DNA vectors upstream RMRP pro-
moter to knockdown RMRP resulted in the early embryonic 
mouse lethality, supporting the hypothesis that RMRP deple-
tion is incompatible with life. With the advances of gene-ed-
iting technologies, further studies could attempt introducing 
single CHH variants into mouse genome rather than aiming 
at complete knockdown of RMRP.
Recently, an RMRP knockout zebrafish created with the 
CRISP/Cas9 technology has been described, with the focus 
on mechanisms leading to chondrodysplasia.14 The absence 
of RMRP expression was detrimental also in zebrafish as mu-
tants survived only for 12-14 days; however, early develop-
mental stages could be examined. This model demonstrated 
impaired chondrogenesis and bone ossification, inhibited cell 
proliferation, as well as increased apoptosis due to dysregu-
lation of genes related to cell cycle and apoptosis. The ab-
normalities in chondrogenesis and bone ossification included 
upregulation of Wnt/β-catenin pathway, and the inhibition of 
Wnt signalling partially alleviated the chondrodysplasia in 
mutant larvae. Further studies of the pathogenesis of immu-
nodeficiency in CHH could benefit from the zebrafish model.
3 |  CLINICAL MANIFESTATIONS 
OF IMMUNODEFICIENCY IN CHH
3.1 | Infections
Table 1 reviews the types, aetiology and frequency of infec-
tions in patients with CHH. Typically, infections include 
recurrent episodes of otitis media, sinusitis and pneumonia, 
caused by common pathogens like Haemophilus influenzae, 
Moraxella catarrhalis and Streptococcus pneumoniae.38,39 
In severe cases, infections with Pneumocystis jiroveci, 
Aspergillus spp, herpes viruses (particularly varicella-zoster 
virus) have been described. Interestingly, not all patients expe-
rience recurrent or severe infections despite clearly impaired 
cellular immunity illustrated by low counts of lymphocyte 
subsets, as well as abnormal lymphocyte proliferation.4,25
3.2 | Lung disease
Patients with CHH can develop a range of pulmonary mani-
festations, including recurrent respiratory tract infections and 
bronchiectasis, asthma and interstitial pneumonitis.40,41 The 
prevalence of bronchiectasis in a random cohort of 34 Finnish 
individuals with CHH is as high as 29%,40 and even higher 
(43%-52%) in more severely affected patient groups.41,42 
Interestingly, CHH patients with bronchiectasis have higher 
counts of T cells and higher levels of immunoglobulin G.40 
This can be explained by increased age, smoking, chronic 
infections or inflammation in the respiratory tract or by 
bronchiectasis-induced systemic immune response.43 Apart 
from bronchiectasis, high rates (18%) of fibrosis-like lung 
changes, as well as fatal cases of lung emphysema, have been 
reported in patients with CHH.40,44
In the Finnish CHH population, almost one third of patients 
are diagnosed with asthma,40 compared to the prevalence of 6% 
in the general Finnish adult population.45 This raises the possi-
bility of incorrect diagnosis, given the absence of spirometry 
reference values for short-statured patients. Incorrect asthma 
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diagnosis should be avoided, as inhaled corticosteroids in 
adults with bronchiectasis increase the risk of lung infections.46 
Therefore, pulmonary imaging is crucial in CHH patients with 
chronic respiratory symptoms to detect bronchiectasis and other 
pulmonary changes. Radiation exposure is an important issue 
in immunodeficient individuals prone to malignancies. Lung 
high-resolution computed tomography is considered the gold 
standard for diagnosing bronchiectasis; however, lung magnetic 
resonance imaging has demonstrated good performance in 
evaluation of bronchiectasis in patients with CHH.40
Given the high prevalence of clinically relevant pulmo-
nary changes in CHH, the reliable performance and safety of 
lung magnetic resonance imaging, scheduled lung imaging, 
should be performed in all adults and in symptomatic chil-
dren with CHH. For asymptomatic patients, lung magnetic 
resonance imaging at baseline can be performed as early as 
possible beginning from the age when patients are able to un-
dergo this diagnostic procedure without the need for general 
anaesthesia. The interval for repeated lung imaging should be 
derived individually based on the patient clinical course and 
respiratory symptoms.
3.3 | Autoimmunity and immune 
dysregulation
Up to 11% of patients with CHH develop autoimmune dis-
eases, with a large spectrum of manifestations, such as 
enteropathy, haemolytic anaemia, hypoparathyroidism, 
hypo- or hyperthyroidism, idiopathic thrombocytopenic 
purpura, juvenile rheumatoid arthritis, multifocal motor ax-
onal neuropathy, narcolepsy, neutropenia and psoriasis.47 
Autoimmunity in adulthood correlates with recurrent pneu-
monia and sepsis episodes and is an independent risk factor 
for mortality in CHH, possibly reflecting the more profound 
immunodeficiency.44,47
Immune dysregulation in CHH can also present with 
hepatosplenomegaly, severe eczema and inflammatory 









Mäkitie 19934 108 0.8-52 >6 uncomplicated URTI or ≥ 3 OM or 
Sin in the preceding year
58/103 (56) OM, Pn, sepsis, severe varicella, Sin, 
URTI
Mäkitie 199862 35 0.1-55 >6 uncomplicated URTI or ≥ 3 OM, 
Sin or Pn per year
11/35 (11) OM, Pn, Sin, URTI
Mäkitie 200063 20 1.7-16 >6 uncomplicated URTI or ≥ 3 OM, 
Sin or Pn in the preceding year
10/20 (50) RTI
Hermanns 200671 27 0.6-32 Inf incidence significantly above 
average in age-matched controls
12/22 (55) RTI or other
Kavadas 200820 12 0.2-6, 44 Inf suggestive of immune deficiency 8/12 (67) OM, Pn (Aspergillus, CMV, PJ), 
thrush
Rider 200961 25 0.8-21 Life-threatening inf prior to age 2 years 
or > 2 bact inf/ year during the first 
2 years of life
8/25 (32) Disseminated HSV, parvovirus; 
meningitis (Haemophilus 
influenzae); OM; Pn (bact, CMV); 
sepsis; Sin; thrush
Bordon 201042 16 0.7-19 All patients required HSCT 16/16 (100) Adeno enteritis and hepatitis; 
disseminated CMV, EBV, HSV; 
OM; Pn (bact, varicella-zoster 
virus); severe varicella
de la Fuente 
201125
18 1-21 Severe and/or recurrent inf, not further 
defined
11/18 (61) EBV-LP, molluscum, parvovirus, Pn 
(Aspergillus, CMV), sepsis, URTI
Ip 201560 13 0-9 All patients required HSCT 13/13 (100) Disseminated adeno, CMV, EBV, 
HHV-6; EBV-LP; enteritis (adeno, 
HHV-6); OM; RTI; severe varicella
Kostjukovits 
201737
56 0.7-68 OM and/or Sin requiring surgical 
interventions, sepsis, Pn, severe warts, 
recurrent and/or severe herpes virus inf
15/56 (27) Boils, mucocutaneous HSV, OM, 
Pn, sepsis, severe varicella, severe 
warts, Sin
Abbreviations: Adeno, adenovirus; bact, bacterial; CMV, cytomegalovirus; EBV, Epstein-Barr virus; EBV-LP, EBV-related lymphoproliferation; HHV-6, human 
herpes virus 6; HSCT, haematopoietic stem cell transplantation; HSV, herpes simplex virus; inf, infection; N, number of patients; OM, otitis media; PJ, Pneumocystis 
jiroveci; Pn, pneumonia; Sin, sinusitis; URTI, upper respiratory tract infection.
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granulomatous skin lesions.41,48,49 Granulomas in CHH may 
be positive for vaccine-strain rubella virus 49 and may be ex-
tremely difficult to treat.48 Importantly, skin granulomas in 
individuals with CHH can also represent an EBV-associated 
lymphomatoid granulomatosis or T-cell lymphoproliferative 
disorder.50,51
Persistent or recurrent diarrhoea can be another feature of 
immune dysregulation in CHH, seen in up to 22% of patients.47 
Some patients demonstrate concomitant duodenal villous at-
rophy despite negative coeliac screen.47,48 Further studies are 
needed to identify the underlying pathology and to establish op-
timal therapy in individuals with CHH suffering from chronic 
diarrhoea to prevent malnutrition and malignant transformation.
The mechanisms behind autoimmunity in CHH remain 
obscure. Although the protein microarray demonstrates 
broad IgG autoantibody multireactivity in serum samples 
of CHH patients compared to healthy controls, no clinical 
correlates have been established.52 However, these findings 
suggest that B-cell dysregulation may contribute to the au-
toimmune manifestations of CHH. A single patient with 
CHH and the absence of FOXP3 + T cells in the thymus 
has been described, underscoring the role of regulatory T 
cells in pathogenesis of immune dysregulation in CHH.53 
Thymic biopsy from this patient showed marked depletion 
of thymocytes, loss of corticomedullary demarcation and 
lack of Hassall corpuscles, suggesting that thymic abnor-
malities can explain the clinical features of Omenn syn-
drome seen in this subject with CHH.53 The numbers of 
regulatory T cells are normal in peripheral blood in pa-
tients with CHH, including subjects with autoimmunity 36; 
however, the function of regulatory T cells has not been 
explored in CHH.
3.4 | Malignancy
Patients with CHH are at increased risk of malignancy, par-
ticularly lymphoma and basal cell carcinoma. Standardized 
incidence ratio (SIR) for any malignancy in Finnish patients 
with CHH is 7.0 compared to the general Finnish popula-
tion, and up to 41% of surviving CHH patients can be esti-
mated to have cancer diagnosis by the age of 65 years.7 The 
most frequent malignancy is non-Hodgkin lymphoma with 
SIR of 90. Median age at lymphoma diagnosis is 33 years, 
and SIR for non-Hodgkin lymphoma is 130 in the age group 
of 15-29 years.7 Skin cancer is also common in CHH, with 
SIR of 33 for basal cell carcinoma.7 The distribution of skin 
cancer in individuals with CHH (face, head and upper limbs) 
implies sun exposure as the main pathogenic mechanism.44
The pathogenesis of malignancy in CHH is multifac-
torial, as patients with no clinical symptoms of immuno-
deficiency can develop malignancy during follow-up.44 
Lymphoproliferative disorders in subjects with CHH have 
been reported to be Epstein-Barr virus-driven in some, but not 
all cases.50,51,54 Hence, not only impaired viral suppression, 
but other mechanisms, such as impaired telomere biology or 
chromosomal instability, may contribute to the increased risk 
of malignancies in CHH.55,56
The impaired control of human papillomavirus (HPV) in-
fection can play an important role in the pathogenesis of cer-
tain malignancies in CHH. Recent studies have reported 1) 
high rates (8/18, 44%) of cervical HPV positivity in women 
with CHH, and 2) correlation of warts with the development 
of skin cancer in individuals with CHH.44,57 Regular gynae-
cological and dermatological evaluation, as well as vaccina-
tion against HPV, should be a standard of care for patients 
with CHH.
Patients with CHH can develop malignancy without any 
previous clinical symptoms of immunodeficiency,44 which 
calls for regular follow-up of mildly symptomatic patients 
with CHH. Early diagnosis of lymphoma either during a 
scheduled screening or through the thorough evaluation for 
non-specific mild symptoms improves survival.44 Fatal lym-
phoma in CHH has been described as early as at the age of six 
years; therefore, screening (clinical, laboratory and by imag-
ing, especially for prolonged or unusual symptoms) should be 
considered early in childhood.58
3.5 | Laboratory features of 
immunodeficiency in CHH
Table 2 demonstrates the variability of blood immunologic pa-
rameters in patients with CHH. The most uniform laboratory 
immunologic feature is the decreased lymphocyte prolifera-
tion responses, demonstrated in the majority of patients (69%-
100%). Other consistent findings include significant reduction 
of recent thymic emigrants, naive T and B cells, low or absent 
T-cell receptor excision circles (TREC) and restricted T-cell 
repertoire.20,36,59 Also, specific antibody deficiency has been 
reported in the majority of evaluated patients with CHH (7/8, 
88%) and can be a marker of a more severe disease course.36
Lower counts of total CD3 + T lymphocytes and of recent 
thymic immigrants in patients with more profound immuno-
deficiency have been observed.36 However, reduced recent 
thymic immigrants can be seen in patients without significant 
clinical immunodeficiency.25 Equivocal associations have 
also been reported between the severity of CHH and lympho-
cyte proliferative responses and other routine immunological 
laboratory indices.20,25,60-62
To further complicate the interpretation of immunologic 
laboratory results in patients with CHH, consideration should 
be given to the fact that laboratory parameters can fluctu-
ate significantly with time.20,63 This poses challenges to both 
management decisions and studies searching for prognostic 
correlates.
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3.6 | Disease course and mortality
Mortality rates are higher in patients with CHH compared with 
the general population. Standardized mortality rates of 7.0-
9.3 in Finnish patients with CHH have been reported.5,44 The 
main causes of deaths include infections in childhood, malig-
nancy in young adulthood and lung disease in adulthood.5,44
Patients with variants other than n.71A  >  G may have 
a more severe immunologic phenotype, but this correlation 
has not been straightforward.20,36 Compound heterozygous 
duplications and triplications of RMRP have been correlated 
with the milder growth failure in CHH.20,58 However, even 
these patients with less severe short stature can exhibit se-
vere immunodeficiency, and therefore, mild growth failure 





N (%) Cell counts, N (%)
Abnormal Ly 
responses to PHA, 
N (%)
Mäkitie 19934 108 0.8-52 NA Ly ↓ 51/79 (65) 53/60 (88)
Mäkitie 199862 35 0.1-55 Normal 16/16 (100) Ly ↓ 12/33 (36)
CD4+ ↓ 17/30 (57)
CD8+ ↓ 8/30 (27) ↑ 1/30 (3)
CD19+ ↓ 2/23 (9) ↑ 2/23 (9)
22/32 (69)
Mäkitie 200063 20 1.7-16 IgG ↓ 0/20 (0) ↑ 5/20 (25)
IgM normal 20/20 (100)
IgA deficiency 2/20 (10)
NA NA
Hermanns 200671 27 0.6-32 Ig-s ↓ 2/5 (40) CD3+ ↓ 6/9 (67) 2/2 (100)
Kavadas 200820 12 0.2-6, 44 IgG ↓ 3/11 (27) ↑ 7/11 
(64)
IgM ↓ 1/11 (9)
IgA deficiency 3/11 (27)
Ly ↓ 10/12 (83)
CD3+ ↓ 12/12 (100)
CD4+ ↓ 11/12 (92)
CD8+ ↓ 12/12 (100)
CD19+ ↓ 6/12 (50)
NK ↓ 2/12 (17)
TREC ↓ 4/5 (80)
11/11 (100)
Rider 200961 25 0.8-21 IgG ↓ or ↑ in some
IgM ↓ in some
IgA deficiency 3/25 (12)
Ly ↓ in the majority In most
Bordon 201042 16 0.7-19 IgG ↓ 5/16 (31)
IgM ↓ 5/16 (31)
IgA ↓ 8/16 (50)
Ly ↓ 15/16 (94)
CD3+ ↓ 15/16 (94)
CD4+ ↓ 15/16 (94)
CD8+ ↓ 15/16 (94)
CD19+ ↓ 12/16 (75)
NK ↓ 2/13 (15)
14/15 (93)
de la Fuente 201125 18 1-21 Normal Ig-s 11/14 (79) CD3+ ↓ 10/18 (56)
CD4+ ↓ 18/18 (100)
CD8+ ↓ 13/18 (72)
CD19+ ↓ 8/18 (44)
RTE ↓ 18/18 (100)
11/13 (85)
Ip 201560 13 0-9 IgG ↓ 4/12 (33) ↑ 2/12 
(17)
IgA ↓ 7/12 (58)
IgM ↓ 5/12 (42)
CD4+ ↓ 13/13 (100)
CD8+ ↓ 9/13 (69)
CD19+ ↓ 5/13 (38)
TREC ↓ 9/9 (100)
9/11 (82)
Kostjukovits 201737 56 0.7-68 IgG ↓ 1/50 (2) ↑ 2/50 (4)
IgA ↓ 2/55 (4)
IgM ↓ 7/55 (13)
Ly ↓ 31/56 (55)
CD3+ ↓ 25/55 (45) ↑ 2/55 (4)
CD4+ ↓ 24/55 (44)
CD8+ ↓ 25/55 (45) ↑ 2/55 (4)
CD19+ ↓37/55 (67)
NK ↓ 4/55 (7)
RTE ↓ 27/52 (52)
NA
Note: CD cluster of differentiation, CD19+ B cells, CD+ T cells, CD4+ helper T cells, CD8+ effector T cells, Ig immunoglobulin, Ly lymphocytes, N number of 
patients, NA not available, NK natural killer cells, PHA phytohemagglutinin, TREC T-cell receptor excision circles, ↓ decreased, ↑ increased.
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should not provide a false sense of mild disease. On the other 
hand, severe short stature at birth (<−4.0 standard deviation) 
clearly correlates with early mortality in CHH.44
Apart from severe short stature at birth, several other clin-
ical features have been described as risk factors for mortality 
in CHH.44 Severe disease course has been demonstrated in 
CHH patients with Hirschsprung disease, pneumonia in the 
first year of life or repeatedly in adulthood and autoimmune 
diseases in adulthood.44,64,65
While immunological laboratory indices correlate poorly 
with clinical disease severity and prognosis in patients with 
CHH, categorization of subjects based on clinical features 
of immunodeficiency has been successfully implemented in 
the assessment of mortality risk in Finnish CHH cohort.44 
Patients can be categorized as follows: (a) asymptomatic 
group with no increased susceptibility to infections, (b) 
subjects with symptoms typical for humoural immunode-
ficiency (recurrent respiratory tract infections and/or sep-
sis), and (c) patients with clinical symptoms of combined 
immunodeficiency such as autoimmunity or opportunistic 
infections. During long-term follow-up, those belonging to 
the combined immunodeficiency group demonstrate signifi-
cantly higher mortality, suggesting that a more aggressive 
treatment approach is justified in these patients. Validation 
of the reported clinical risk factors for mortality is needed to 
determine, whether they can be used to guide management 
decisions in patients outside the original Finnish cohort.
Immunodeficiency is progressive in CHH. A 30-year fol-
low-up demonstrated that in 22% of patients, (17/79) clini-
cal symptoms of immunodeficiency progressed with time.44 
These data highlight the importance of regular follow-up of 
asymptomatic or mildly symptomatic patients with CHH.
Variants in RMRP have also been described to cause a 
somewhat controversial disease entity—metaphyseal dys-
plasia without hypotrichosis (MDWH, OMIM #250460).66 
MDWH is characterized by the metaphyseal dysplasia iden-
tical to CHH, but in the absence of extra-skeletal manifes-
tations like hypotrichosis or immunodeficiency. Recently, 
late-onset immunodeficiency and development of malig-
nancies in adulthood have been demonstrated in patients 
with RMRP variants and MDWH features in childhood.67 
Interestingly, these subjects had less profound growth failure 
at birth. These findings suggest that MDWH represent cases 
of CHH with risk of late-onset complications and call for reg-
ular and careful follow-up of individuals with RMRP variants 
and isolated skeletal features.
4 |  MANAGEMENT OF 
IMMUNODEFICIENCY IN CHH
All patients with CHH should be regularly assessed for the 
symptoms and signs of immunodeficiency. Management of 
recurrent respiratory infections in CHH does not differ from 
other primary immunodeficiency disorders and includes 
prevention by immunizations (including pneumococcal and 
annual influenza vaccines), antibiotic prophylaxis or immu-
noglobulin replacement therapy in selected cases.
Given the high prevalence of pulmonary issues in 
CHH, regular lung function assessment and lung imaging 
should be considered, especially in symptomatic patients. 
Bronchiectasis should be diagnosed promptly and man-
aged aggressively to prevent end-organ lung damage, which 
contributes significantly to mortality in adults with CHH. 
Treatment options for bronchiectasis include pulmonary re-
habilitation and physiotherapy, as well as antibiotics, partic-
ularly macrolides.46 Prolonged treatment with clarithromycin 
has resulted in the improvement of bronchiectasis in one 
child with CHH and lung disease.38
Prevention of malignancy is crucial in CHH and should 
include common recommendations, such as sun protection, 
advice against smoking, minimizing radiation exposure from 
radiologic imaging, as well as encouragement of HPV immu-
nizations. Screening for malignancy should be a routine in pa-
tients with CHH, including regular dermatologic examination 
for skin cancer, gynaecologic assessment and cervical cancer 
screening, as well as proper clinical, laboratory (at least com-
plete blood count and sedimentation rate) and radiologic (ab-
dominal ultrasound and other imaging as needed) evaluation 
for lymphoma.
Over 40 patients with CHH who had required haemato-
poietic stem cell transplantation (HSCT) have been reported, 
with follow-up of 0.75-20 years and with combined survival 
rate of 76% post-transplant.65 Deaths are attributed mostly to 
infectious complications, but also to severe graft-versus-host 
disease.41,59,68 The majority of HSCT survivors restore nor-
mal immunity.41,59 HSCT can stabilize or improve pulmonary 
function and halt the progression of pre-existing bronchiecta-
sis in CHH.41 HSCT can also correct the immune dysregula-
tion, such as autoimmunity or inflammatory skin lesions.41,48 
Also, in patients with primary immunodeficiency disorders, 
HSCT decreases the risk of malignancies, which is an im-
portant consideration in CHH.69
While HSCT is a straightforward choice in CHH pa-
tients with severe combined immunodeficiency or per-
sistent transfusion-dependent anaemia, in the remaining 
majority of subjects, the indications for HSCT are not so 
clear-cut. HSCT should be considered on an individual 
basis in CHH, and ideally should be performed before the 
development of severe opportunistic infections, signif-
icant organ damage or malignancy. Laboratory parame-
ters correlate poorly with the disease course in CHH 36,44; 
therefore, with the exception of individuals fulfilling the 
criteria for severe combined immunodeficiency, the se-
lection of patients who would benefit from HSCT based 
solely on routinely available laboratory parameters is 
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problematic. However, newborn screening for severe com-
bined immunodeficiency identifies patients with CHH 
and may guide early management. TREC counts measured 
in the newborn screening have been previously assessed 
in patients with CHH of various age and shown to be low 
or absent in all evaluated subjects.20,59 Recently, in a small 
study, TREC counts obtained via newborn screening in 
eight CHH patients correlated with clinical severity and 
various immunologic laboratory parameters.65 If these 
findings are confirmed in larger studies with longer fol-
low-up period, TREC counts may become the most im-
portant prognostic indicator in CHH.
Patients with CHH can present with variable clinical fea-
tures, and the spectrum of manifestations include orthopae-
dic, infectious, haematologic, pulmonary, gastrointestinal, 
endocrinologic, gynaecologic, as well as rehabilitation is-
sues. Therefore, a multidisciplinary team should provide care 
for patients with CHH, to ensure timely and accurate evalua-
tion, therapy and follow-up.
5 |  CONCLUSIONS AND FUTURE 
PROSPECTS
Cartilage-hair hypoplasia is a syndromic primary immuno-
deficiency disorder with complex pathogenesis and vari-
able clinical course. Recent advances have shed light on the 
mechanisms underlying immunodeficiency in CHH, such as 
cell cycle disturbances, impaired telomere maintenance and 
altered gene regulation. However, further research is needed 
to explain the variability of clinical and laboratory features, 
as well as differences in the clinical course and mortality 
among patients with CHH. With the rapid development of 
small-molecule therapeutics and gene-editing technologies, 
potential molecular targets and the possibility of gene ther-
apy should be explored in CHH. Clinical guidelines for the 
management of CHH should be developed to optimize pa-
tient care.
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